MartinS.RheeMD

Internal Medicine • Brockton, MA

Infectious Disease

Assistant Professor, Medicine, Tufts Medical Center

Join to view full profile

Are you Dr. Rhee?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
You already have 7 invites waiting!
Read the latest clinical news, personalized to your specialty.

Claim this profile

Not you? Find your profile

Office
680 Centre St
Brockton, MA 02302
Phone+1 508-941-7000

Fax+1 508-941-6337

Summary

Dr. Martin Rhee, MD is an internist in Brockton, Massachusetts. He is an Assistant Professor at Tufts Medical Center.

Education & Training

Tufts Medical CenterFellowship, Infectious Disease, 2004 - 2008
Dartmouth-Hitchcock/Mary Hitchcock Memorial HospitalResidency, Internal Medicine, 2000 - 2003
Seoul National University College of MedicineClass of 1998

Clinical Trials

Study of Treatment of Antiretroviral-naive, HIV-1-Infected Patients Comparing Tenofovir Disoproxil Fumarate Administered in Combination With Lamivudine and Efavirenz vs. Stavudine, Lamivudine and Efavirenz. Start of enrollment: 2000 Mar 01
Completed
Phase 3
Safety of EVG+RTV Administered With Other Antiretroviral Agents for the Treatment of HIV-1 Infection Start of enrollment: 2007 Feb 01
Completed
Phase 2
Study to Evaluate the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults Start of enrollment: 2010 Mar 01
Completed
Phase 3
Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV Start of enrollment: 2014 Jan 16
Recruiting
Phase 2, Phase 3
Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF Start of enrollment: 2014 May 06
Completed
Phase 3
Renal Effect of Stribild or Other Tenofovir DF-containing Regimens Compared to Ritonavir-boosted Atazanavir Plus Abacavir/Lamivudine in Antiretroviral Treatment-naive HIV-1 Infected Adults Start of enrollment: 2014 Dec 15
Completed
Phase 4
Join now to see all

Publications & Presentations

PubMed

30 citations
Absence of Lenacapavir (GS-6207) Phenotypic Resistance in HIV Gag Cleavage Site Mutants and in Isolates with Resistance to Existing Drug Classes.
Nicolas A. Margot, Renee Ram, Martin S. Rhee, Christian Callebaut
Antimicrobial Agents and Chemotherapy. 2021-02-17
193 citations
Clinical targeting of HIV capsid protein with a long-acting small molecule.
John O. Link, Martin S. Rhee, Tse Winston C, Jim Zheng, John R. Somoza
Nature. 2020-07-01
22 citations
Tenofovir alafenamide plus emtricitabine versus abacavir plus lamivudine for treatment of virologically suppressed HIV-1-infected adults: a randomised, double-blind, a...
Alan Winston, Frank A. Post, Edwin DeJesus, Daniel Podzamczer, Giovanni Di Perri
The Lancet. HIV. 2018-04-01

Press Mentions

An HIV Drug You Only Take Twice a Year?July 1st, 2020
Experimental HIV Drug Seems Effective at a Twice-a-year Dose, Study FindsJuly 1st, 2020